• Home
  • Search
  • Cost of Illness Studiesin clinical depression Using Discounting Methods: A Comprehensive Analysis
  • https://doi.org/10.53555/ajbr.v27i3s.2989Copy DOI Icon

Cost of Illness Studiesin clinical depression Using Discounting Methods: A Comprehensive Analysis

Show More
  • Abstract
  • Literature Map
  • Similar Papers
Abstract

Abstract:This research delves into the intricate domain of Cost of Illness (COI) studies, also known as Burden of Disease (BOD), with a specific focus on depressive disorders. Employing a bottom-up approach, the study meticulously scrutinizes the economic implications of depression at various levels, emphasizing direct and indirect costs. The analysis integrates a detailed exploration of diverse discounting methods, including Net Present Value (NPV) and Discounted Cash Flow (DCF), with a particular emphasis on the Indian context to comprehend unique socio-economic factors.Methodologically, the study systematically reviews scientific literature over the past decade, utilizing databases such as Web of Science and Google Scholar. The inclusion criteria prioritize patient-based studies related to the cost of illness associated with depression. The research adopts a comprehensive approach, considering various methodologies and discounting techniques to enhance the understanding of economic implications.The comparative analysis of the total cost of illness across diverse countries unravels significant variations, highlighting the intricate nature of healthcare expenditures and economic structures. Specific breakdowns for each country consider factors suchas currency exchange rates, inflation, and Purchasing Power Parity (PPP) adjustments, shedding light on the complexities involved.The study across five countries highlights significant variations in depression-related costs. Direct medical costs have a mean of $42,668 (SD=16,940) with a high t-statistic of 27.83 (p-value 0.001), emphasizing substantial differences. Direct non-medicalcosts average $27,171 (SD=13,220) with a t-statistic of 14.07 (p-value 0.001), indicating a notable economic burden beyond medical expenses. Indirect costs related to depression stand at a mean of $63,816 (SD=25,230), with a t-statistic of 35.30 (p-value 0.001), highlighting significant impacts on productivity and societal costs. The total cost of illness, encompassing both direct and indirect costs, averages $113,590 (SD=43,990), with a t-statistic of 49.49 (p-value 0.001), reflecting the extensive economic implications of depression across these diverse nations.In conclusion, this comprehensive analysis contributes depth to our understanding of the economic impact of depressive disorders, providing valuable insights for policymakers, healthcare providers, and researchers. The research underscores the multifacetednature of the economic burden of depression, emphasizing variations across countries and advocating for comprehensive, context-specific approaches in assessing and addressing global implications. Acknowledging challenges with discounting methods, the paper identifies opportunities for refining methodologies and improving economic evaluations in the future, emphasizing the importance of nuanced insights for effective policymaking and healthcare strategies on a global scale.

Similar Papers
  • Research Article
  • Citations9

Unseen Costs: The Direct and Indirect Impact of U.S. Immigration Policies on Child and Adolescent Health and Well-Being.

  • Aug 13, 2020
  • Journal of Traumatic Stress
  • T Joseph Mattingly +6
  • Research Article
  • Citations3

COST OF ILLNESS OF INPATIENT PEDIATRIC MENINGITIS PATIENTS HOSPITALIZED IN YOGYAKARTA

  • Apr 26, 2020
  • Jurnal farmasi sains dan praktis
  • Ingenida Hadning +3
  • Research Article
  • Citations150

Cost of Illness and its Predictors for Parkinson??s Disease in Germany

  • Jan 01, 2005
  • PharmacoEconomics
  • Annika E Spottke +13
  • Research Article
  • Citations30

Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020.

  • Apr 03, 2022
  • Epilepsia
  • Laurent M Willems +14
  • PDF
  • Research Article
  • Citations8

Cost of illness studies in COVID-19: a scoping review

  • Jan 18, 2024
  • Cost effectiveness and resource allocation : C/E
  • Majid Nakhaee +2
  • Research Article
  • Citations27

Costs of illness and quality of life in patients with systemic lupus erythematosus in South Korea

  • Feb 21, 2014
  • Lupus
  • Jh Cho +9
  • PDF
  • Research Article
  • Citations2

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia

  • Sep 09, 2014
  • Journal Infectology
  • В Рудакова +3
  • Research Article
  • Citations23

The Cost of Illness of Hypertension and Associated Factors at the University of Gondar Comprehensive Specialized Hospital Northwest Ethiopia, 2018

  • Mar 06, 2020
  • ClinicoEconomics and Outcomes Research: CEOR
  • Elsabet Adane +2
  • Abstract

Sa1071 Direct and Indirect Costs Associated With Barrett's Esophagus Screening: Results From a Community Randomized Controlled Trial

  • Apr 01, 2015
  • Gastroenterology
  • James Moriarty +5
  • Research Article
  • Citations1

Societal costs of decreased visual acuity: A Finnish cohort study with 15 years of registry data follow-up.

  • Jan 20, 2025
  • Acta ophthalmologica
  • Joonas Taipale +5
  • Research Article
  • Citations1

Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies

  • Nov 20, 2024
  • BMC Health Services Research
  • Ione Woollacott +8
  • Research Article
  • Citations4

Estimates of Direct Medical and Indirect Costs Associated With COVID-19 Among U.S. Active Duty Army Soldiers.

  • Oct 08, 2022
  • Military Medicine
  • Lanna Forrest +6
  • Research Article
  • Citations184

Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States

  • Apr 13, 2011
  • Journal of Allergy and Clinical Immunology
  • Dipen A Patel +3
  • Abstract

Cost of Care of Rare Hematologic Disorders in the United States: Call to Action for Policy Supporting Pharmacologic Innovation

  • Nov 05, 2021
  • Blood
  • Pedro Andreu Perez +5
  • Research Article
  • Citations829

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

  • Jun 19, 2012
  • Diabetic Medicine
  • N Hex +4
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.